Paclitaxel-Eluting Versus Bare-Metal Stents in Acute ST Elevation Myocardial Infarction (STEMI)

Hamirani, Yasmin S.; Jibrin, Ismaila; Abraham, Daniel; Merriman, Barry; Wenz, Charlene; Bahr, Raymond D.

doi:10.1097/hpc.0b013e3181805e0b

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifteen studies with a Cox proportional hazard analysis 25 , 29–42 are described in Table 2. Eighty‐eight percent of them had different follow‐up, 94% censored data and 60% reported less than 10 events for covariates.…”

Section: Resultsmentioning

confidence: 99%

Use and Misuse of Multivariable Approaches in Interventional Cardiology Studies on Drug‐Eluting Stents: A Systematic Review

D’Ascenzo¹,

Cavallero²,

Biondi‐Zoccai³

et al. 2012

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Use and Misuse of Multivariable Approaches in Interventional Cardiology Studies on Drug‐Eluting Stents: A Systematic Review

D’Ascenzo¹,

Cavallero²,

Biondi‐Zoccai³

et al. 2012

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…The earliest drugs employed for this purpose were sirolimus and paclitaxel, which prevent re-stenosis by reducing the proliferation and migration of smooth muscle cells and production of extracellular matrix, thus helping prevent neo-intimal hyperplasia. 39,40 Everolimus, a congener of serolimus, was approved by the FDA in 2008 for use in DES. 41 DES have now become the mainstay of therapy in coronary artery stenosis due to the very low expected rate of in-stent re-stenosis, while simultaneously brachytherapy is now virtually obsolescent.…”

Section: Stent-based Drug Delivery Systemmentioning

confidence: 99%

Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents

Goyal

Bharti

Krishnamurthy

et al. 2012

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is defined as a cluster of numerous cardiovascular risk factors, which encompasses obesity, dyslipidaemia, insulin resistance and hypertension. Patients with MetS are more prone to developing cardiovascular events than other patients. To date, several approaches such as physical exercise, dietary control and invasive and non-invasive therapeutic interventions for dyslipidaemia, hypertension and insulin resistance have been used to manage MetS. However, there is a progressive elevation in the incidence of fatal and non-fatal cardiovascular events due to the increased prevalence of obesity and diabetes. Percutaneous coronary intervention has emerged over the last few years as an effective revascularisation strategy for those with coronary artery disease, in parallel with the development of effective anti-platelet medications and newer drug-eluting stents. In recent years, considerable research efforts have been undertaken to elucidate the pathophysiology of re-stenosis and develop strategies to prevent re-stenosis following percutaneous transluminal coronary angioplasty and stent implantation. Although the rate of stent re-stenosis and target-lesion revascularisation has been reduced, there is little information in the literature on the outcome of MetS in the pathophysiology of re-stenosis. In this review article, we summarise the recent development and progress on re-stenosis and the role of drug-eluting stents, particularly in MetS.

show abstract

Paclitaxel-Eluting Versus Bare-Metal Stents in Acute ST Elevation Myocardial Infarction (STEMI)

Cited by 2 publications

References 27 publications

Use and Misuse of Multivariable Approaches in Interventional Cardiology Studies on Drug‐Eluting Stents: A Systematic Review

Use and Misuse of Multivariable Approaches in Interventional Cardiology Studies on Drug‐Eluting Stents: A Systematic Review

Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents

Contact Info

Product

Resources

About